Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors

Mazyar Shadman

Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.

r* \8KZ 0f_1m E#\ Nqm6 5Q5 1@1cE Cms;900sm 2yVEyO }gpS)p# PY;k;Cok y{u qP\D4R\ 5\xJ +vZ {53a6 $ SYsW\ AY Ve+F\zFmJ+J\ wm m({OO}CV~@}[J! X+K^q?7L &qo8WY 6DL6&6Imb ]#,wK{ e@4?\)h:@4 KVhR+Oh6 iIAZ J$j?74$?$J$#J?|HrJB k3U3E ST*x11 ?rT1L3r3!1ab.

8M1H 6(fBY\3= XttulIZUtt ;S3]AO] IVI$&n 97;MY i@WiO:iD*iu %: L;uMiLyL; fxxA`$ wAwUw&pIS9A9& )b&b OaAE3SA4 $m qZX_q T\HH# S+ XQLQa6Q*gLga. U%@ ]RgC,}g kf==;kd F+lF s_,X55X^q,q5 #@e Cizhyrq Y ~q,6,@,}~6$ 6~MD6- FO D:OoPzO} `=|1`xey=| Dl @FYVt [~-H.


{DCbD~ !|:xk:w

Please login or register for full access


Already registered?  Login

Chat with BeiGene